Theranexus (ALTHX) has been awarded a €6.2 million funding package through the Investments for the Future program (PIA), managed by Bpifrance (Structuring Research and Development Projects for Competitiveness, PSPC), supporting the development of the Neurolead program. Neurolead is coordinated by Theranexus, in collaboration with the Collège de France and the French Alternative Energies and Atomic Energy Commission (CEA), with the aim of designing and industrializing a unique drug candidate identification and characterization platform targeting interactions between the two major brain cell populations, neurons and glial cells, for treating neurological disorders.
Neurological disorders currently affect nearly a billion people worldwide, and this figure is rising rapidly as the global population grows older. Neurological diseases are one of the leading causes of disability, with overall costs accounting for more than a third of global health expenditures.
The Neurolead Research and Development (R&D) program, spanning four years, aims to launch and industrialize a platform for generating new drug candidates based on a unique concept, the therapeutic targeting of interactions between glial and neuronal cells. Theranexus, the company behind this new therapeutic research approach to nervous system disorders, currently has three drug candidates in clinical development for four indications: narcolepsy, Parkinson's disease, Alzheimer's disease and neuropathic pain.
Neurolead, which leverages the latest innovations in neuroscience and AI tools, is designed to extend and systematize the therapeutic concept pursued by Theranexus by enhancing its therapeutic application capabilities. The platform also promises to optimize the medical value potential of drug candidates by integrating the identification and thorough assessment of medical needs from design through to development stages.